Navigation Links
Greenberg Traurig London Team Represents Long-time Client AstraZeneca AB in Two Divestment Agreements
Date:11/9/2018

The London office of global law firm Greenberg Traurig, LLP represented AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of USD700 million with further sales-related and milestone payments of up to USD90 million. Nexium (esomeprazole) is a proton pump inhibitor that decreases the amount of acid produced in the stomach. The law firm also represented AstraZeneca AB on its agreement with Grünenthal to divest the global rights to Vimovo in all markets excluding the US and Japan for an upfront payment of USD115 million and further payments up to another USD17 million. Vimovo combines the non-steroidal anti-inflammatory drug naproxen with esomeprazole, the active ingredient in Nexium, for patients a risk of developing ulcers.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Grünenthal is a science-based pharmaceutical company specialised in innovative pain management and related therapies. These divestments are part of several transactions in which Greenberg Traurig’s London office has represented AstraZeneca over the past eight years.

The deal was led by Adam McArthur and Warren Brown, in-house lawyers at AstraZeneca AB. Greenberg Traurig team members involved in these latest transactions included: Paul Maher, Vice Chair of Greenberg Traurig; Fiona Adams, Co-Managing Shareholder of the London office and the Co-Chair of the firm’s Global Corporate Practice; shareholders Henrietta Walker and Sarah Moyles; associates David Hirschman, Charlotte Irvine, Miles Daly, Eleni Pittas, and Declan Grady; and IP Consultant Ewen Mitchell.

“It has been an absolute pleasure to represent AstraZeneca and to work with Adam and Warren, its dynamic and commercially driven legal team,” Maher said. “We are proud to have been able to help them achieve AstraZeneca’s strategic divestment goals.”

About Greenberg Traurig’s Corporate Practice
Greenberg Traurig’s Corporate Practice comprises more than 450 lawyers in the United States, Europe, Asia, the Middle East and Latin America who regularly advise public and privately held companies, entrepreneurs and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, consumer products, energy, food and beverage, health care, manufacturing, media, technology, and telecommunications sectors.

About Greenberg Traurig’s London Office: Greenberg Traurig, LLP in London has established itself as a multidisciplinary law firm, with more than 80 lawyers and growing. The London office provides partner-led advice to domestic and international clients on a range of matters across the legal spectrum. Lawyers at Greenberg Traurig in London advise U.K. and multinational clients operating in many different sectors, including chemicals, pharmaceuticals, life sciences, energy, real estate, financial services, automotive, retail, and communications.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2018 Am Law Global 100. Web: http://www.gtlaw.com; Twitter: @GT_Law.

Read the full story at https://www.prweb.com/releases/greenberg_traurig_london_team_represents_long_time_client_astrazeneca_ab_in_two_divestment_agreements/prweb15906696.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Archbishop Desmond Tutu Advocates St John International Charity Work on Packed London Visit and Audience with HM The Queen
2. UKs Flagship Health & Safety Event Has Successful Inaugural Year in London
3. genae Opens Offices in London
4. FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database
5. Klinische Studie von LKC Technologies bestätigt kosteneffektive Alternative zum Goldstandard beim Screening auf diabetische Retinopathie. Einzelheiten werden beim EURETINA/ESCRS in London bekanntgegeben
6. NW BIO CEO TO PRESENT AT SMis 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON
7. FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online
8. FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à lASHG 2014
9. Process Validation in the US and EU (Workshop, London)
10. New Cancer Center at Guys Hospital in London to be Equipped with Varian TrueBeam Treatment Machines
11. TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2018)... ... November 16, 2018 , ... Dr. Michael Goldberger of the Foot & Ankle ... as well as new winter shoes to the area’s homeless in collaboration with his team ... second year the event will take place at the Isaiah House, located at 238 N. ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... Dry Shampoo Collection that quickly refreshes and restores hair between washes. , ... comprised of three different products, including an instant drying foam that can be ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... engaged as exclusive financial advisor on a $2 million convertible note investment ... field. Toolbox Genomics is dedicated to becoming the healthcare industry’s gold standard ...
Breaking Medicine Technology:
(Date:11/16/2018)... ... November 16, 2018 , ... ... organization as a behavioral service provider dedicated to continuous improvement in Applied ... areas of clinical quality, staff qualifications, and consumer satisfaction and promote systems ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... offer treatment options to patients suffering from chronic pelvic pain. In addition ... treatment of various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... function in the female reproductive system. However, changes in the color, smell, or ... can be embarrassing and bothersome and result in a low self-esteem for many ...
(Date:11/16/2018)... ... November 16, 2018 , ... A promising new product can ... can improve compliance early in the development of new drugs. Market research ... is estimated at $7.8 billion, boosted by developments in implants, pumps, and microfluidics, ...
(Date:11/16/2018)... ... November 16, 2018 , ... AP was selected in the Health Care 2 ... December 6, 2018 at the Hyatt Regency Downtown Dallas along with other companies who ... to move on to the Annual Excellence in Construction National Level Competition through Associated ...
Breaking Medicine News(10 mins):